Last reviewed · How we verify
NCT05409417
Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
Phase 2, PHASE3 trial testing Experimental drug in Colorectal Cancer in 40 participants. Status unknown.
1 February 2024
Quick facts
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 October 2022 |
| Primary completion | 1 February 2024 |
| Estimated completion | 1 September 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Experimental drug — full drug profile →
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Liver Metastases — all drugs for Liver Metastases →
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Who can join
Adults 18 to 75, any sex, with Colorectal Cancer or Liver Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluation of tislellimab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab regimen in patients with liver metastases from colorectal cancer Rate and R0 resection rate and safety.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review.
Guven DC, Kavgaci G, Erul E, Syed MP, et al · · 2024 · cited 35× · PMID 38309719 · DOI 10.1093/oncolo/oyae013 -
The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives.
Gandini A, Puglisi S, Pirrone C, Martelli V, et al · · 2023 · cited 29× · PMID 37207140 · DOI 10.3389/fonc.2023.1161048 -
The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies.
Wang Q, Yu M, Zhang S. · · 2024 · cited 19× · PMID 39877377 · DOI 10.3389/fimmu.2024.1440830 -
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.
Villarruel-Melquiades F, Mendoza-Garrido ME, García-Cuellar CM, Sánchez-Pérez Y, et al · · 2023 · cited 14× · PMID 37213397 · DOI 10.3748/wjg.v29.i17.2571
Verify or expand the search:
- PubMed search for NCT05409417
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Experimental drug
Trials testing the same drug.
- NCT06752382 — Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC · Phase 2 · not yet recruiting
- NCT05451654 — NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evalu · Phase 1, PHASE2 · terminated
- NCT04357613 — IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS. · Phase 2 · unknown
- NCT04001439 — FEcal Microbiota Transplantation · NA · unknown
- NCT03821870 — Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity · completed
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials
Trials by the same sponsor.
- NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
- NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
- NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
- NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
- NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05409417 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
- Last refreshed: 8 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05409417.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing